Three HHMI scientists are among 11 honored for excellence in research aimed at curing intractable diseases and extending human life.
HHMI researcher and colleagues design and develop drug that prolongs survival in men with advanced prostate cancer.
New research offers a genetic explanation for why some patients' lung tumors disappear almost completely when treated with the drug erlotinib, while other patients' responses are far less dramatic.
The discovery of an odd couple of genes that team up to trigger rare and difficult-to-detect gastrointestinal stromal tumors could eventually lead to better diagnostics and treatments.
HHMI investigators Brian Druker and Charles Sawyers will join Nicholas Lydon, formerly of Novartis, in receiving the 2009 Lasker~Debakey Clinical Medical Research Award.
HHMI researchers identify many potential new drug targets for cancers long deemed "untouchable."
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.
Meet the 15 physician-scientists selected in 2007 as new HHMI investigators.
An experimental drug reverses the signs and symptoms of patients whose chronic myeloid leukemia has failed to respond to Gleevec.
HHMI researchers have discovered how a new generation of drugs thwarts a deadly mutation that causes chronic myelogenous leukemia.
An experimental drug shows early promise in reversing the signs and symptoms of patients whose chronic myeloid leukemia failed to respond to Gleevec.
HHMI researchers report the first description of a new compound that is designed to overcome Gleevec resistance in chronic myeloid leukemia.
HHMI researchers have discovered that drug resistance arises in prostate cancers through a relatively straightforward mechanism.